UK Medical Cannabis Registry: An Updated Analysis of Cannabis-Based Medicinal Products for Multiple Sclerosis
CBMP treatment over 24 months was associated with improvements in health-related quality of life and was well tolerated in patients with MS. Future randomised controlled trials with more representative study populations are needed to establish causal relationships.
Authors
- Ross Coomber (ORCID: https://orcid.org/0000-0002-8144-1996)
- Simon Erridge (ORCID: https://orcid.org/0000-0001-5871-6501)
- Mark W Weatherall (ORCID: https://orcid.org/0000-0002-0051-9107)
- James Rucker (ORCID: https://orcid.org/0000-0003-4647-8088)
- Kaitlyn McLachlan (ORCID: https://orcid.org/0000-0003-4569-7529)
- Mikael H. Sodergren (ORCID: https://orcid.org/0000-0002-7141-3924)
- Eleanor Clarke (ORCID: https://orcid.org/0000-0002-2150-2283)
- Yogesh Shah (ORCID: https://orcid.org/0009-0000-5090-1331)
Institutions
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- Buckinghamshire Healthcare NHS Trust (GB)
- St George's Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Medical Cannabis and Cannabinoids
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1159/000549178
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00